IMC Chicago
REGN icon

IMC Chicago’s Regeneron Pharmaceuticals REGN Stock Holding History

IMC Chicago’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.5M Buy
114,700
+16,100
+16% +$11M 0.02% 471
2026
Q1 		$76.2M Sell
98,600
-22,300
-18% -$17.1M 0.03% 364
2025
Q4 		$93.3M Buy
120,900
+900
+0.8% +$611K 0.03% 304
2025
Q3 		$67.5M Buy
120,000
+8,300
+7% +$4.69M 0.02% 374
2025
Q2 		$58.6M Buy
111,700
+41,500
+59% +$23.2M 0.03% 343
2025
Q1 		$44.5M Buy
70,200
+28,500
+68% +$19.6M 0.03% 349
2024
Q4 		$29.7M Buy
41,700
+31,700
+317% +$26.6M 0.01% 473
2024
Q3 		$10.5M Sell
10,000
-1,500
-13% -$1.67M 0.01% 797
2024
Q2 		$12.1M Sell
11,500
-2,600
-18% -$2.52M 0.01% 713
2024
Q1 		$13.6M Sell
14,100
-10,300
-42% -$9.79M 0.01% 593
2023
Q4 		$21.4M Buy
24,400
+7,900
+48% +$6.51M 0.01% 438
2023
Q3 		$13.6M Sell
16,500
-33,200
-67% -$26.1M 0.01% 471
2023
Q2 		$35.7M Buy
49,700
+12,100
+32% +$9.33M 0.03% 254
2023
Q1 		$30.9M Buy
37,600
+15,400
+69% +$11.6M 0.04% 249
2022
Q4 		$16M Sell
22,200
-4,000
-15% -$2.95M 0.03% 357
2022
Q3 		$18M Buy
+26,200
New +$16.5M 0.02% 311
2022
Q1 		– Sell
-23,700
Closed -$15M – 1208
2021
Q4 		$15M Sell
23,700
-18,000
-43% -$11.1M 0.01% 415
2021
Q3 		$25.2M Buy
41,700
+16,300
+64% +$10.1M 0.03% 311
2021
Q2 		$14.2M Sell
25,400
-19,500
-43% -$9.88M 0.02% 392
2021
Q1 		$21.2M Sell
44,900
-28,200
-39% -$13.7M 0.03% 277
2020
Q4 		$35.3M Buy
73,100
+38,000
+108% +$20.5M 0.05% 173
2020
Q3 		$19.6M Sell
35,100
-4,300
-11% -$2.61M 0.03% 210
2020
Q2 		$24.6M Sell
39,400
-11,900
-23% -$6.75M 0.05% 130
2020
Q1 		$25M Sell
51,300
-500
-1% -$206K 0.05% 115
2019
Q4 		$19.4M Buy
51,800
+38,700
+295% +$13M 0.05% 132
2019
Q3 		$3.63M Sell
13,100
-13,200
-50% -$3.91M 0.01% 348
2019
Q2 		$8.23M Buy
26,300
+7,300
+38% +$2.43M 0.03% 200
2019
Q1 		$7.8M Sell
19,000
-5,200
-21% -$2.14M 0.03% 175
2018
Q4 		$9.04M Buy
+24,200
New +$8.86M 0.03% 131

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

IMC Chicago's REGN Position: Q2 2026 in Review

IMC Chicago opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 5,591 shares worth $3.49M. The stake represents ﹤0.01% of the portfolio and ranks #2494 among its holdings. This is a return to the name: IMC Chicago previously reported a position in REGN as recently as Q2 2025.

IMC Chicago first reported a position in REGN in Q2 2025 and has held it in 2 quarters since. The position peaked at $9.42M in Q2 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • IMC Chicago held 5,591 shares of Regeneron Pharmaceuticals worth $3.49M as of Q2 2026.
  • Regeneron Pharmaceuticals was a new IMC Chicago position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #2494 holding.
  • IMC Chicago first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • IMC Chicago's Regeneron Pharmaceuticals position peaked at $9.42M in Q2 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.